|
US6660753B2
(en)
|
1999-08-19 |
2003-12-09 |
Nps Pharmaceuticals, Inc. |
Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
KR100838447B1
(ko)
*
|
2001-02-21 |
2008-06-16 |
아스트라제네카 아베 |
헤테로폴리시클릭 화합물 및 대사향성 글루타메이트수용체 길항제로서의 그의 용도
|
|
US6916821B2
(en)
|
2001-04-02 |
2005-07-12 |
Brown University |
Methods of treating disorders with Group I mGluR antagonists
|
|
AU2002307049A1
(en)
|
2001-04-02 |
2002-10-15 |
Brown University Research Foundation |
Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
|
|
US7105548B2
(en)
*
|
2001-12-18 |
2006-09-12 |
Merck & Co., Inc. |
Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
|
|
JP4286146B2
(ja)
*
|
2001-12-18 |
2009-06-24 |
メルク エンド カムパニー インコーポレーテッド |
メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤
|
|
EP1458385A4
(en)
*
|
2001-12-19 |
2005-12-21 |
Merck & Co Inc |
METABOTROPIC GLUTAMATE RECEPTOR 5-HETEROARYL-SUBSTITUTED IMIDAZOLE MODULATORS
|
|
WO2003077918A1
(en)
*
|
2002-03-12 |
2003-09-25 |
Merck & Co., Inc. |
Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
|
|
SE0201943D0
(sv)
*
|
2002-06-20 |
2002-06-20 |
Astrazeneca Ab |
New use
|
|
US7964609B2
(en)
|
2002-06-20 |
2011-06-21 |
Astrazeneca Ab |
Use of mGluR5 antagonists for the treatment of gerd
|
|
AU2003268064A1
(en)
*
|
2002-08-09 |
2004-02-25 |
Astrazeneca Ab |
Oxadiazoles as modulators of metabotropic glutamate receptor-5
|
|
AU2003264018A1
(en)
*
|
2002-08-09 |
2004-02-25 |
Astrazeneca Ab |
Compounds having an activity at metabotropic glutamate receptors
|
|
KR20050033070A
(ko)
|
2002-08-09 |
2005-04-08 |
아스트라제네카 에이비이 |
메타보트로픽 글루타메이트 수용체-5의 조절제로서[1,2,4]옥사디아졸
|
|
GB0303503D0
(en)
*
|
2003-02-14 |
2003-03-19 |
Novartis Ag |
Organic compounds
|
|
US7268151B2
(en)
*
|
2003-04-04 |
2007-09-11 |
Merck & Co., Inc. |
Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
|
|
JP2006528980A
(ja)
*
|
2003-05-15 |
2006-12-28 |
メルク エンド カムパニー インコーポレーテッド |
Ｓ１ｐ受容体作働薬としての３−（２−アミノ−１−アザシクロ）−５−アリール−１，２，４−オキサジアゾール類
|
|
WO2005060961A2
(en)
*
|
2003-12-18 |
2005-07-07 |
Astrazeneca Ab |
Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
|
|
CN1898235A
(zh)
|
2003-12-24 |
2007-01-17 |
普罗西迪恩有限公司 |
作为gpcr受体激动剂的杂环衍生物
|
|
US7585881B2
(en)
|
2004-02-18 |
2009-09-08 |
Astrazeneca Ab |
Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
NZ548693A
(en)
*
|
2004-02-18 |
2010-05-28 |
Astrazeneca Ab |
Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
AU2005214380A1
(en)
|
2004-02-18 |
2005-09-01 |
Astrazeneca Ab |
Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
|
|
EP1716152B1
(en)
*
|
2004-02-18 |
2008-07-30 |
AstraZeneca AB |
Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
|
|
CA2570318A1
(en)
*
|
2004-06-30 |
2006-01-12 |
Banyu Pharmaceutical Co., Ltd. |
Biaryl derivatives
|
|
KR100621192B1
(ko)
*
|
2004-10-13 |
2006-09-19 |
한국화학연구원 |
무스카린 수용체 작용물질로서 작용하는1,2,3,4-테트라하이드로피리미디닐-1,2,4-옥사다이아졸유도체와 이의 제조방법
|
|
JP4557685B2
(ja)
|
2004-11-15 |
2010-10-06 |
独立行政法人理化学研究所 |
蛍光蛋白質
|
|
MX2007008410A
(es)
|
2005-01-14 |
2007-08-21 |
Hoffmann La Roche |
Derivados de tiazol-4-carboxamida como antagonistas de receptor de glutamato metabotropico 5-.
|
|
GB0510142D0
(en)
*
|
2005-05-18 |
2005-06-22 |
Addex Pharmaceuticals Sa |
Novel compounds A1
|
|
WO2007001973A1
(en)
*
|
2005-06-28 |
2007-01-04 |
Astrazeneca Ab |
New use
|
|
CA2616377C
(en)
|
2005-07-26 |
2014-04-01 |
David Alexander Learmonth |
Nitrocatechol derivatives as comt inhibitors
|
|
AR058807A1
(es)
|
2005-09-29 |
2008-02-27 |
Astrazeneca Ab |
5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
|
|
ES2382162T3
(es)
|
2005-11-08 |
2012-06-05 |
F. Hoffmann-La Roche Ag |
Derivados de tiazolo[4,5-c]piridina como antagonistas de receptor MGLU5
|
|
US7951824B2
(en)
|
2006-02-17 |
2011-05-31 |
Hoffman-La Roche Inc. |
4-aryl-pyridine-2-carboxyamide derivatives
|
|
TWI382984B
(zh)
*
|
2006-04-03 |
2013-01-21 |
Astellas Pharma Inc |
雜環化合物
|
|
EP1845097A1
(en)
|
2006-04-10 |
2007-10-17 |
Portela & Ca., S.A. |
Oxadiazole derivatives as COMT inhibitors
|
|
EP2255848A3
(en)
*
|
2006-09-04 |
2011-04-06 |
NeuroSearch AS |
Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
|
|
AU2007292993B2
(en)
|
2006-09-07 |
2013-01-24 |
Idorsia Pharmaceuticals Ltd |
Pyridin-4-yl derivatives as immunomodulating agents
|
|
MX2009002234A
(es)
|
2006-09-08 |
2009-03-16 |
Actelion Pharmaceuticals Ltd |
Derivados de piridin-3-il como agentes inmunomoduladores.
|
|
MX2009002915A
(es)
|
2006-09-21 |
2009-03-31 |
Actelion Pharmaceuticals Ltd |
Derivados de fenilo y su uso como inmunomoduladores.
|
|
EP2481410B1
(en)
|
2007-01-31 |
2016-07-13 |
BIAL - Portela & Ca., S.A. |
Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime
|
|
NZ580454A
(en)
|
2007-03-16 |
2011-05-27 |
Actelion Pharmaceuticals Ltd |
Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
|
|
PT2195311E
(pt)
|
2007-08-17 |
2011-05-25 |
Actelion Pharmaceuticals Ltd |
Derivados de piridina como moduladores do receptor s1p1/edg1
|
|
EP2215049B1
(en)
|
2007-10-31 |
2019-06-12 |
Merck Sharp & Dohme Corp. |
P2x3, receptor antagonists for treatment of pain
|
|
CA2700917A1
(en)
|
2007-11-01 |
2009-05-07 |
Actelion Pharmaceuticals Ltd |
Novel pyrimidine derivatives
|
|
SG186679A1
(en)
*
|
2007-12-20 |
2013-01-30 |
Bayer Schering Pharma Ag |
4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof
|
|
AU2009212135B2
(en)
*
|
2008-02-07 |
2014-08-21 |
Massachusetts Eye & Ear Infirmary |
Compounds that enhance Atoh-1 expression
|
|
JP5481395B2
(ja)
|
2008-03-07 |
2014-04-23 |
アクテリオン ファーマシューティカルズ リミテッド |
新規なアミノメチルベンゼン誘導体
|
|
TW200942531A
(en)
|
2008-03-17 |
2009-10-16 |
Bial Portela & Companhia S A |
Crystal forms of a nitrocatechol
|
|
EP2358371B1
(en)
|
2008-10-31 |
2015-02-11 |
Merck Sharp & Dohme Corp. |
P2x3, receptor antagonists for treatment of pain
|
|
DE102008057344A1
(de)
|
2008-11-14 |
2010-05-20 |
Bayer Schering Pharma Aktiengesellschaft |
Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
|
|
DE102009041242A1
(de)
|
2009-09-11 |
2011-12-15 |
Bayer Schering Pharma Aktiengesellschaft |
Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
|
|
DE102008057343A1
(de)
|
2008-11-14 |
2010-05-20 |
Bayer Schering Pharma Aktiengesellschaft |
Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
|
|
DE102009041241A1
(de)
|
2009-09-11 |
2011-08-04 |
Bayer Schering Pharma Aktiengesellschaft, 13353 |
Substituierte Aryl-Verbindungen und ihre Verwendung
|
|
DE102008057364A1
(de)
|
2008-11-14 |
2010-05-20 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte Aryl-Verbindungen und ihre Verwendung
|
|
WO2010111060A1
(en)
|
2009-03-23 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
P2x3, receptor antagonists for treatment of pain
|
|
WO2010111059A1
(en)
|
2009-03-23 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
P2x3 receptor antagonists for treatment of pain
|
|
AU2010229142A1
(en)
|
2009-03-23 |
2011-10-13 |
Merck Sharp & Dohme Corp. |
P2X3, receptor antagonists for treatment of pain
|
|
KR20210009441A
(ko)
|
2009-04-01 |
2021-01-26 |
바이알 - 포르텔라 앤드 씨에이 에스에이 |
니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
|
|
KR20120022927A
(ko)
*
|
2009-04-13 |
2012-03-12 |
아이알엠 엘엘씨 |
레티놀 결합 단백질 4 (ｒｂｐ4)에 대한 레티놀 결합을 조절하기 위한 조성물 및 방법
|
|
SI2454255T1
(sl)
|
2009-07-16 |
2014-01-31 |
Actelion Pharmaceuticals Ltd. |
Derivati piridin-4-ila kot agonisti s1p1/edg1
|
|
WO2011109398A2
(en)
|
2010-03-02 |
2011-09-09 |
President And Fellows Of Harvard College |
Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
|
|
KR101869120B1
(ko)
|
2011-01-19 |
2018-06-19 |
이도르시아 파마슈티컬스 리미티드 |
2-메톡시-피리딘-4-일 유도체
|
|
US20140045900A1
(en)
|
2011-02-11 |
2014-02-13 |
Bial-Portela & Ca, S.A. |
Administration regime for nitrocatechols
|
|
PT2791134T
(pt)
|
2011-12-13 |
2019-12-18 |
BIAL PORTELA & Cª S A |
Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase
|
|
JP5946288B2
(ja)
*
|
2012-02-24 |
2016-07-06 |
公立大学法人名古屋市立大学 |
新規ヒドロキサム酸誘導体及びその用途
|
|
EP2956453B1
(en)
*
|
2013-02-15 |
2019-10-02 |
Monsanto Technology LLC |
3,5-disubstituted-4,5-dihydro-1,2,4-oxadiazoles for controlling nematode pests
|
|
EP2853532B1
(en)
*
|
2013-09-28 |
2020-12-09 |
Instytut Farmakologii Polskiej Akademii Nauk |
1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
|
|
JP2018500300A
(ja)
|
2014-11-28 |
2018-01-11 |
ノヴィファーマ，エス．アー． |
パーキンソン病を遅延させるための医薬
|
|
ES2770348T3
(es)
|
2015-05-20 |
2020-07-01 |
Idorsia Pharmaceuticals Ltd |
Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1,2-diol
|
|
JP6454418B2
(ja)
|
2015-06-23 |
2019-01-16 |
キッセイ薬品工業株式会社 |
ピラゾール誘導体、またはその薬理学的に許容される塩
|
|
BR112018069868A2
(pt)
*
|
2016-03-30 |
2019-01-29 |
Sinntaxis AB |
modulador alostérico negativo do receptor metabotrópico de glutamato 5, usos de um nam, e método de tratamento ou atenuação de dano cerebral maduro
|
|
CA3096746A1
(en)
*
|
2018-04-12 |
2019-10-17 |
Bayer Aktiengesellschaft |
N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}benzamide derivatives and the corresponding pyridine-carboxamide derivatives as pesticides
|
|
KR102276327B1
(ko)
*
|
2019-06-25 |
2021-07-12 |
연세대학교 산학협력단 |
신규 옥사다이아졸 화합물 및 이를 포함하는 당뇨 예방 또는 치료용 조성물
|
|
US20230114241A1
(en)
*
|
2019-09-05 |
2023-04-13 |
Trevena, Inc. |
Methods of treating epilepsy using the same
|